Aurobindo Pharma is trading higher by 3% to Rs 161 after the company said it has received tentative approval from the US Food & Drug Administration (USFDA) to manufacture and market anti-AIDS combination drug Efavirenz/ Emtricitabine and Tenofovir Disoproxil Fumarate Tablets.
“The company is one of the first generics firm to have received the tentative approval to manufacture and market its anti-AIDS combination drug Efavirenz / Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 600mg/200mg/300mg from the USFDA,” Aurobindo Pharma said in a BSE filing.
The drug is the generic equivalent of Gilead Sciences Inc’s Atripla® Tablets 600mg/200mg/300mg and falls under the Anti-Retroviral (ARV) segment, it added.
Meanwhile, the stock has outperformed the market by surging 24% in past four trading sessions on BSE after USFDA has lifted the import alert for Unit VI Cephalosporin facility, which allows company to resume the supply of 9 products to US market from the same unit. The benchmark Sensex has gained 1.5% during the same period.
The stock opened at Rs 157 and hit a high of Rs 163 on BSE. A combined 3.61 million shares have changed hands on the counter so far on BSE and NSE.
“The company is one of the first generics firm to have received the tentative approval to manufacture and market its anti-AIDS combination drug Efavirenz / Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 600mg/200mg/300mg from the USFDA,” Aurobindo Pharma said in a BSE filing.
The drug is the generic equivalent of Gilead Sciences Inc’s Atripla® Tablets 600mg/200mg/300mg and falls under the Anti-Retroviral (ARV) segment, it added.
Meanwhile, the stock has outperformed the market by surging 24% in past four trading sessions on BSE after USFDA has lifted the import alert for Unit VI Cephalosporin facility, which allows company to resume the supply of 9 products to US market from the same unit. The benchmark Sensex has gained 1.5% during the same period.
The stock opened at Rs 157 and hit a high of Rs 163 on BSE. A combined 3.61 million shares have changed hands on the counter so far on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%